Who are Exondys 51's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qalsody, Amondys 45, Vyondys 53, Kynamro, PF-07852352 Influenza saRNA 1, ISIS 3521.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eteplirsen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Exondys 51 — Competitive Intelligence Brief

Exondys 51 (ETEPLIRSEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense Oligonucleotide [EPC]. Area: Rare Disease.

marketed Antisense Oligonucleotide [EPC] exon 51 of dystrophin pre-mRNA Rare Disease Oligonucleotide Live · refreshed every 30 min

Target snapshot

Exondys 51 (ETEPLIRSEN) — Sarepta. Exondys 51 binds to specific RNA sequences to prevent the skipping of exon 51 during dystrophin mRNA splicing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exondys 51 TARGET	ETEPLIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	2016-01-01
Qalsody	TOFERSEN	Biogen Ma	marketed	Antisense Oligonucleotide [EPC]	Superoxide dismutase 1 (SOD1) mRNA	2023-01-01
Amondys 45	CASIMERSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2021-01-01
Vyondys 53	GOLODIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2019-01-01
Kynamro	MIPOMERSEN	Kastle Theraps Llc	marketed	Antisense Oligonucleotide		2013-01-01
PF-07852352 Influenza saRNA 1	pf-07852352-influenza-sarna-1	Pfizer	marketed	antisense oligonucleotide	influenza virus
ISIS 3521	ISIS 3521	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Antisense oligonucleotide	Protein kinase C-alpha (PKC-alpha) mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense Oligonucleotide [EPC] class)

Sarepta · 3 drugs in this class
Biogen Ma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exondys 51 — Competitive Intelligence Brief. https://druglandscape.com/ci/eteplirsen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab